SK Bioscience targets PCV21 launch in 2029: 2027 results guide SK Bioscience stock

Published on 10/19/2026 at 00:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PCV21 results are due in 2027. SK Bioscience stock last closed at KRW 36,300.00 on October 16, 2026, with launch targeted for 2029.

PCV21 timeline and earnings

SK Bioscience is targeting PCV21 commercialization in 2029 after Phase 3 results expected in 2027.
Second-quarter 2026 revenue fell 3.80 percent to KRW 156.0 billion, while the operating loss was KRW 15.7 billion.
The KRX close was KRW 36,300.00 on October 16, 2026.

SK Bioscience, KR7302440003, Illustration mit AI erstellt.

SK Bioscience is targeting commercialization of its PCV21 vaccine in 2029, while major Phase 3 results are expected in 2027, according to Seoul Economic Daily on October 6, 2026. The timeline gives investors a longer-term growth case while the current vaccine business remains under pressure.

Three milestones set the timeline

The company reported revenue of KRW 156.0 billion in the second quarter of 2026, down 3.80 percent from a year earlier, and an operating loss of KRW 15.7 billion, according to ATS View. In the second quarter of 2026, IDT Biologika revenue rose 0.20 percent year over year, helping offset weaker vaccine sales.

The chronology is clear: second-quarter 2026 results showed KRW 156.0 billion of revenue; on October 2, 2026, SK Bioscience introduced new Skycellflu advertising with actor Lee Min-jung, according to SK Bioscience; and on October 6, 2026, the PCV21 plan included KRW 300.0 billion of long-term development funding.

What does PCV21 mean for earnings?

The answer depends on execution rather than the launch date alone. Seoul Economic Daily reported projected PCV21 sales of KRW 120.0 billion to KRW 220.0 billion in 2030 and 2031, while Heungkuk Securities maintained a buy rating and a KRW 52,000 target on October 6, 2026. That view rests on the IDT contract manufacturing business, higher-value contracts and progress in Phase 3 trials.

Upcoming dates for investors

The next major development is the expected PCV21 Phase 3 result in 2027, followed by the targeted commercial launch in 2029. These are company milestones rather than near-term earnings dates, so the second-quarter loss remains the immediate operating reference.

KRX close adds the market context

SK Bioscience last closed at KRW 36,300.00 on the KRX on October 16, 2026. The contrast between that market level and the KRW 52,000 target cited by Heungkuk Securities highlights the market's dependence on clinical progress and a recovery in operating performance.